Molecular genetic characterization of lymphoma: Application to cytology diagnosis

Diagnostic Cytopathology

Volumn 40, Issue 6, 2012, Pages 542-555

  Ochs, Rachel C ^a   Bagg, Adam ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

cytology; FISH; lymphoma; molecular; PCR

Indexed keywords

CD20 ANTIGEN; CD23 ANTIGEN; CD3 ANTIGEN; CD30 ANTIGEN; CD5 ANTIGEN; CD79A ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLIN D1; CYCLIN D2; CYCLIN D3; IMMUNOGLOBULIN HEAVY CHAIN; INTERFERON REGULATORY FACTOR 4; KI 67 ANTIGEN; MYC PROTEIN; PROTEIN BCL 10; PROTEIN BCL 2; PROTEIN BCL 6; PROTEIN KINASE ZAP 70; PROTEIN P53;

ASPIRATION BIOPSY; B CELL LYMPHOMA; BREAST CANCER; BURKITT LYMPHOMA; CANCER DIAGNOSIS; CANCER RISK; CHROMOSOME TRANSLOCATION; CHRONIC LYMPHATIC LEUKEMIA; CLONAL VARIATION; CONFERENCE PAPER; CYTOGENETICS; CYTOPATHOLOGY; ENTEROPATHY; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLICULAR LYMPHOMA; GENE DELETION; GENE LOCATION; GENE MUTATION; GENE OVEREXPRESSION; GENE TARGETING; GENE TRANSLOCATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GERMINAL CENTER; HASHIMOTO DISEASE; HUMAN; IMMUNOPHENOTYPING; KAPOSI SARCOMA; LARGE CELL LYMPHOMA; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC THYROIDITIS; LYMPHOCYTOMA; LYMPHOID HYPERPLASIA; LYMPHOMA; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; MOLECULAR GENETICS; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; PAROTID GLAND CANCER; POLYMERASE CHAIN REACTION; PRIMARY EFFUSION LYMPHOMA; PRIORITY JOURNAL; PROLYMPHOCYTIC LEUKEMIA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SJOEGREN SYNDROME; SOMATIC HYPERMUTATION; T CELL LYMPHOMA;

CELL PROLIFERATION; CHROMOSOMES, HUMAN; CYTODIAGNOSIS; DNA-BINDING PROTEINS; EARLY DETECTION OF CANCER; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, B-CELL; LYMPHOMA, T-CELL; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MYC; SENSITIVITY AND SPECIFICITY; THYROID NEOPLASMS; TRANSLOCATION, GENETIC;

EID: 84861565707     PISSN: 87551039     EISSN: 10970339     Source Type: Journal    
DOI: 10.1002/dc.22819     Document Type: Conference Paper

References (118)

1. Stoos-Veic T, Livun A, Ajdukovic R, Pejsa V, Jaksic O, Kusec R,. Detection of t(14;18) by PCR of IgH/BCL2 fusion gene in follicular lymphoma from archived cytological smears. Coll Antropol 2010; 34: 425-429.
2. da Cunha Santos G, Ko HM, Geddie WR, et al. Targeted use of fluorescence in situ hybridization (FISH) in cytospin preparations: Results of 298 fine needle aspirates of B-cell non-Hodgkin lymphoma. Cancer Cytopathol 2010; 118: 250-258.
3. Killian JK, Walker RL, Suuriniemi M, et al. Archival fine-needle aspiration cytopathology (FNAC) samples: Untapped resource for clinical molecular profiling. J Mol Diagn 2010; 12: 739-745.
4. Monaco SE, Teot LA, Felgar RE, Surti U, Cai G,. Fluorescence in situ hybridization studies on direct smears: An approach to enhance the fine-needle aspiration biopsy diagnosis of B-cell non-Hodgkin lymphomas. Cancer 2009; 117: 338-348.
5. Safley AM, Buckley PJ, Creager AJ, et al. The value of fluorescence in situ hybridization and polymerase chain reaction in the diagnosis of B-cell non-Hodgkin lymphoma by fine-needle aspiration. Arch Pathol Lab Med 2004; 128: 1395-1403.
6. Schmid S, Tinguely M, Cione P, Moch H, Bode B,. Flow cytometry as an accurate tool to complement fine needle aspiration cytology in the diagnosis of low grade malignant lymphomas. Cytopathology 2011; 22:397-406.
7. Bangerter M, Brudler O, Heinrich B, Griesshamnuer M,. Fine needle aspiration cytology and flow cytometry in the diagnosis and subclassification of non-Hodgkin's lymphoma based on the World Health Organization classification. Acta Cytol 2007; 51: 390-398.
8. Demurtas A, Accinelli G, Pacchioni D, et al. Utility of flow cytometry immunophenotyping in fine-needle aspirate cytologic diagnosis of non-Hodgkin lymphoma: A series of 252 cases and review of the literature. Appl Immunohistochem Mol Morphol 2010; 18: 311-322.
9. Liu K, Stern RC, Rogers RT, Dodd LG, Mann KP,. Diagnosis of hematopoietic processes by fine-needle aspiration in conjunction with flow cytometry: A review of 127 cases. Diagn Cytopathol 2001; 24: 1-10.
10. Bagg A,. Immunoglobulin and T-cell receptor gene rearrangements: Minding your B's and T's in assessing lineage and clonality in neoplastic lymphoproliferative disorders. J Mol Diagn 2006; 8: 426-429; quiz526-527.
11. Roullet M, Bagg A,. The basis and rational use of molecular genetic testing in mature B-cell lymphomas. Adv Anat Pathol 2010; 17: 333-358.
12. Jaffe ES, Banks PM, Nathwani B, Said J, Swerdlow SH,. Recommendations for the reporting of lymphoid neoplasms: A report from the Association of Directors of Anatomic and Surgical Pathology. Mod Pathol 2004; 17: 131-135.
13. Maroto A, Martinez M, Martinez MA, de Agustin P, Rodriguez-Peralto JL,. Comparative analysis of immunoglobulin polymerase chain reaction and flow cytometry in fine needle aspiration biopsy differential diagnosis of non-Hodgkin B-cell lymphoid malignancies. Diagn Cytopathol 2009; 37: 647-653.
14. Zhang S, Abreo F, Lowery-Nordberg M, Veillon DM, Cotelingam JD,. The role of fluorescence in situ hybridization and polymerase chain reaction in the diagnosis and classification of lymphoproliferative disorders on fine-needle aspiration. Cancer Cytopathol 2010; 118: 105-112.
15. Venkatraman L, Catherwood MA, Patterson A, Lioe TF, McCluggage WG, Anderson NH,. Role of polymerase chain reaction and immunocytochemistry in the cytological assessment of lymphoid proliferations. J Clin Pathol 2006; 59: 1160-1165.
16. de Leval L, Hasserjian RP,. Diffuse large B-cell lymphomas and burkitt lymphoma. Hematol Oncol Clin North Am 2009; 23: 791-827.
17. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997; 89: 3909-3918.
18. Swerdlow SH, Campo E, Harris NL, et al., editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. International agency for research on cancer, Lyon, France, 2008.
19. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-511.
20. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 1937-1947.
21. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275-282.
22. Choi WW, Weisenburger DD, Greiner TC, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res 2009; 15: 5494-5502.
23. Colomo L, Lopez-Guillermo A, Perales M, et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood 2003; 101: 78-84.
24. Meyer PN, Fu K, Greiner TC, et al. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol 2011; 29: 200-207.
25. Muris JJ, Meijer CJ, Vos W, et al. Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma. J Pathol 2006; 208: 714-723.
26. Fu K, Weisenburger DD, Choi WW, et al. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. J Clin Oncol 2008; 26: 4587-4594.
27. Gutierrez-Garcia G, Cardesa-Salzmann T, Climent F, et al. Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Blood 2011; 117: 4836-4843.
28. Ott G, Ziepert M, Klapper W, et al. Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL. Blood 2010; 116: 4916-4925.
29. Iqbal J, Meyer PN, Smith L, et al. BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab. Clin Cancer Res, in press.
30. Pasqualucci L, Migliazza A, Basso K, Houldsworth J, Chaganti RS, Dalla-Favera R,. Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma. Blood 2003; 101: 2914-2923.
31. Shustik J, Han G, Farinha P, et al. Correlations between BCL6 rearrangement and outcome in patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP. Haematologica 2010; 95: 96-101.
32. Tzankov A, Schneider A, Hoeller S, Dirnhofer S,. Prognostic importance of BCL6 rearrangements in diffuse large B-cell lymphoma with respect to Bcl6 protein levels and primary lymphoma site. Hum Pathol 2009; 40: 1055-1056; author reply1056.
33. Chang CM, Schroeder JC, Huang WY, et al. Non-Hodgkin lymphoma (NHL) subtypes defined by common translocations: Utility of fluorescence in situ hybridization (FISH) in a case-control study. Leuk Res 2010; 34: 190-195.
34. Hirose Y, Masaki Y, Karasawa H, et al. Incidence of diffuse large B-cell lymphoma of germinal center B-cell origin in whole diffuse large B-cell lymphoma: Tissue fluorescence in situ hybridization using t(14;18) compared with immunohistochemistry. Int J Hematol 2005; 81: 48-57.
35. Tibiletti MG, Martin V, Bernasconi B, et al. BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: A multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome. Hum Pathol 2009; 40: 645-652.
36. Barrans S, Crouch S, Smith A, et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol 2010; 28: 3360-3365.
37. Elkins CT, Wakely PE, Jr,. Cytopathology of "double-hit" non-Hodgkin lymphoma. Cancer Cytopathol 2011; 119: 263-271.
38. Aster JC, Longtine JA,. Detection of BCL2 rearrangements in follicular lymphoma. Am J Pathol 2002; 160: 759-763.
39. Gollub W, Stassek B, Huckhagel T, et al. BCL6-translocations affect the phenotype of follicular lymphomas only in the absence of t(14;18)IgH/BCL2. Anticancer Res 2009; 29: 4649-4655.
40. Bacon CM, Ye H, Diss TC, et al. Primary follicular lymphoma of the testis and epididymis in adults. Am J Surg Pathol 2007; 31: 1050-1058.
41. Swerdlow SH,. Pediatric follicular lymphomas, marginal zone lymphomas, and marginal zone hyperplasia. Am J Clin Pathol 2004; 122 (Suppl): S98-S109.
42. Aguilera NS, Tomaszewski MM, Moad JC, Bauer FA, Taubenberger JK, Abbondanzo SL,. Cutaneous follicle center lymphoma: A clinicopathologic study of 19 cases. Mod Pathol 2001; 14: 828-835.
43. Mirza I, Macpherson N, Paproski S, et al. Primary cutaneous follicular lymphoma: An assessment of clinical, histopathologic, immunophenotypic, and molecular features. J Clin Oncol 2002; 20: 647-655.
44. Richmond J, Bryant R, Trotman W, Beatty B, Lunde J,. FISH detection of t(14;18) in follicular lymphoma on Papanicolaou-stained archival cytology slides. Cancer 2006; 108: 198-204.
45. Baro C, Espinet B, Salido M, et al. Cryptic IGH/BCL2 rearrangements with variant FISH patterns in follicular lymphoma. Leuk Res 2011; 35: 256-259.
46. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910-1916.
47. Migliazza A, Bosch F, Komatsu H, et al. Nucleotide sequence, transcription map, and mutation analysis of the 13q14 chromosomal region deleted in B-cell chronic lymphocytic leukemia. Blood 2001; 97: 2098-2104.
48. Dicker F, Herholz H, Schnittger S, et al. The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype. Leukemia 2009; 23: 117-124.
49. Trbusek M, Smardova J, Malcikova J, et al. Missense mutations located in structural p53 DNA-binding motifs are associated with extremely poor survival in chronic lymphocytic leukemia. J Clin Oncol 2011; 29: 2703-2708.
50. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111: 5446-5456.
51. Caraway NP, Gu J, Lin P, Romaguera JE, Glassman A, Katz R,. The utility of interphase fluorescence in situ hybridization for the detection of the translocation t(11;14)(q13;q32) in the diagnosis of mantle cell lymphoma on fine-needle aspiration specimens. Cancer 2005; 105: 110-118.
52. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK,. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94: 1848-1854.
53. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94: 1840-1847.
54. Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003; 348: 1764-1775.
55. Roullet M, Sargent R, Pasha T, et al. ZAP70 expression assessed by immunohistochemistry on peripheral blood: A simple prognostic assay for patients with chronic lymphocytic leukemia. Appl Immunohistochem Mol Morphol 2007; 15: 471-476.
56. Abboudi Z, Patel K, Naresh KN,. Cyclin D1 expression in typical chronic lymphocytic leukaemia. Eur J Haematol 2009; 83: 203-207.
57. Bentz JS, Rowe LR, Anderson SR, Gupta PK, McGrath CM,. Rapid detection of the t(11;14) translocation in mantle cell lymphoma by interphase fluorescence in situ hybridization on archival cytopathologic material. Cancer 2004; 102: 124-131.
58. Wlodarska I, Dierickx D, Vanhentenrijk V, et al. Translocations targeting CCND2, CCND3, and MYCN do occur in t(11;14)-negative mantle cell lymphomas. Blood 2008; 111: 5683-5690.
59. Metcalf RA, Zhao S, Anderson MW, et al. Characterization of D-cyclin proteins in hematolymphoid neoplasms: Lack of specificity of cyclin-D2 and D3 expression in lymphoma subtypes. Mod Pathol 2010; 23: 420-433.
60. Chen YH, Gao J, Fan G, Peterson LC,. Nuclear expression of sox11 is highly associated with mantle cell lymphoma but is independent of t(11;14)(q13;q32) in non-mantle cell B-cell neoplasms. Mod Pathol 2010; 23: 105-112.
61. Mozos A, Royo C, Hartmann E, et al. SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica 2009; 94: 1555-1562.
62. Suarez F, Lortholary O, Hermine O, Lecuit M,. Infection-associated lymphomas derived from marginal zone B cells: A model of antigen-driven lymphoproliferation. Blood 2006; 107: 3034-3044.
63. Remstein ED, Dogan A, Einerson RR, et al. The incidence and anatomic site specificity of chromosomal translocations in primary extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) in North America. Am J Surg Pathol 2006; 30: 1546-1553.
64. Liu H, Ye H, Ruskone-Fourmestraux A, et al. T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication. Gastroenterology 2002; 122: 1286-1294.
65. Remstein ED, Kurtin PJ, James CD, Wang XY, Meyer RG, Dewald GW,. Mucosa-associated lymphoid tissue lymphomas with t(11;18)(q21;q21) and mucosa-associated lymphoid tissue lymphomas with aneuploidy develop along different pathogenetic pathways. Am J Pathol 2002; 161: 63-71.
66. Zhang W, Garces J, Dong HY,. Detection of the t(11;18) API2/MALT1 translocation associated with gastric MALT lymphoma in routine formalin-fixed, paraffin-embedded small endoscopic biopsy specimens by robust real-time RT-PCR. Am J Clin Pathol 2006; 126: 931-940.
67. Dierlamm J, Baens M, Stefanova-Ouzounova M, et al. Detection of t(11;18)(q21;q21) by interphase fluorescence in situ hybridization using API2 and MLT specific probes. Blood 2000; 96: 2215-2218.
68. Kobayashi Y, Nakata M, Maekawa M, et al. Detection of t(I 1; 18) in MALT-type lymphoma with dual-color fluorescence in situ hybridization and reverse transcriptase-polymerase chain reaction analysis. Diagn Mol Pathol 2001; 10: 207-213.
69. Streubel B, Lamprecht A, Dierlamm J, et al. T(14;18)(q32;q21) involving IGH and MALT1 is a frequent chromosomal aberration in MALT lymphoma. Blood 2003; 101: 2335-2339.
70. Streubel B, Vinatzer U, Lamprecht A, Raderer M, Chott A,. T(3;14)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma. Leukemia 2005; 19: 652-658.
71. Sagaert X, Laurent M, Baens M, Wlodarska I, de Wolf-Peeters C,. MALT1 and BCL10 aberrations in MALT lymphomas and their effect on the expression of BCL10 in the tumour cells. Mod Pathol 2006; 19: 225-232.
72. Hsi ED, Greenson JK, Singleton TP, Siddiqui J, Schnitzer B, Ross CW,. Detection of immunoglobulin heavy chain gene rearrangement by polymerase chain reaction in chronic active gastritis associated with Helicobacter pylori. Hum Pathol 1996; 27: 290-296.
73. Zeppa P, Cozzolino I, Peluso AL, et al. Cytologic, flow cytometry, and molecular assessment of lymphoid infiltrate in fine-needle cytology samples of Hashimoto thyroiditis. Cancer 2009; 117: 174-184.
74. Piccaluga PP, de Falco G, Kustagi M, et al. Gene expression analysis uncovers similarity and differences among Burkitt lymphoma subtypes. Blood 2011; 117: 3596-3608.
75. Boerma EG, Siebert R, Kluin PM, Baudis M,. Translocations involving 8q24 in Burkitt lymphoma and other malignant lymphomas: A historical review of cytogenetics in the light of todays knowledge. Leukemia 2009; 23: 225-234.
76. Lossos IS,. Molecular pathogenesis of diffuse large B-cell lymphoma. J Clin Oncol 2005; 23: 6351-6357.
77. Hummel M, Bentink S, Berger H, et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med 2006; 354: 2419-2430.
78. Salaverria I, Siebert R,. The gray zone between Burkitt's lymphoma and diffuse large B-cell lymphoma from a genetics perspective. J Clin Oncol 2011; 29: 1835-1843.
79. Rapkiewicz A, Wen H, Sen F, Das K,. Cytomorphologic examination of anaplastic large cell lymphoma by fine-needle aspiration cytology. Cancer 2007; 111: 499-507.
80. Ng WK, Ip P, Choy C, Collins RJ,. Cytologic and immunocytochemical findings of anaplastic large cell lymphoma: Analysis of ten fine-needle aspiration specimens over a 9-year period. Cancer 2003; 99: 33-43.
81. Medeiros LJ, Elenitoba-Johnson KS,. Anaplastic large cell lymphoma. Am J Clin Pathol 2007; 127: 707-722.
82. Das DK,. Serous effusions in malignant lymphomas: A review. Diagn Cytopathol 2006; 34: 335-347.
83. Ong KC, Indumathi V, Poh WT, Ong YY,. The diagnostic yield of pleural fluid cytology in malignant pleural effusions. Singapore Med J 2000; 41: 19-23.
84. Johnston WW,. The malignant pleural effusion. A review of cytopathologic diagnoses of 584 specimens from 472 consecutive patients. Cancer 1985; 56: 905-909.
85. Okada F, Ando Y, Kondo Y, Matsumoto S, Maeda T, Mori H,. Thoracic CT findings of adult T-cell leukemia or lymphoma. AJR Am J Roentgenol 2004; 182: 761-767.
86. Carbone A, Gloghini A, Vaccher E, Marchetti G, Gaidano G, Tirelli U,. KSHV/HHV-8 associated lymph node based lymphomas in HIV seronegative subjects. Report of two cases with anaplastic large cell morphology and plasmablastic immunophenotype. J Clin Pathol 2005; 58: 1039-1045.
87. Brimo F, Michel RP, Khetani K, Auger M,. Primary effusion lymphoma: A series of 4 cases and review of the literature with emphasis on cytomorphologic and immunocytochemical differential diagnosis. Cancer 2007; 111: 224-233.
88. Boulanger E, Agbalika F, Maarek O, et al. A clinical, molecular and cytogenetic study of 12 cases of human herpesvirus 8 associated primary effusion lymphoma in HIV-infected patients. Hematol J 2001; 2: 172-179.
89. Lobo C, Amin S, Ramsay A, Diss T, Kocjan G,. Serous fluid cytology of multicentric Castleman's disease and other lymphoproliferative disorders associated with Kaposi sarcoma-associated herpes virus: A review with case reports. Cytopathology, in press.
90. Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM,. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 1995; 332: 1186-1191.
91. Gupta N, Nijhawan R, Srinivasan R, et al. Fine needle aspiration cytology of primary thyroid lymphoma: A report of ten cases. Cytojournal 2005; 2: 21.
92. Derringer GA, Thompson LD, Frommelt RA, Bijwaard KE, Heffess CS, Abbondanzo SL,. Malignant lymphoma of the thyroid gland: A clinicopathologic study of 108 cases. Am J Surg Pathol 2000; 24: 623-639.
93. Watanabe N, Noh JY, Narimatsu H, et al. Clinicopathological features of 171 cases of primary thyroid lymphoma: A long-term study involving 24,553 patients with Hashimoto's disease. Br J Haematol, in press.
94. Widder S, Pasieka JL,. Primary thyroid lymphomas. Curr Treat Options Oncol 2004; 5: 307-313.
95. Kaba S, Hirokawa M, Kuma S, et al. Cytologic findings of primary thyroid MALT lymphoma with extreme plasma cell differentiation: FNA cytology of two cases. Diagn Cytopathol 2009; 37: 815-819.
96. Al-Marzooq YM, Chopra R, Younis M, Al-Mulhim AS, Al-Mommatten MI, Al-Omran SH,. Thyroid low-grade B-cell lymphoma (MALT type) with extreme plasmacytic differentiation: Report of a case diagnosed by fine-needle aspiration and flow cytometric study. Diagn Cytopathol 2004; 31: 52-56.
97. Kojima M, Nakamura N, Shimizu K, Segawa A, Kaba S, Masawa N,. MALT type lymphoma demonstrating prominent plasma cell differentiation resembling fibrous variant of Hashimoto's thyroiditis: A three case report. Pathol Oncol Res 2009; 15: 285-289.
98. Chen HI, Akpolat I, Mody DR, et al. Restricted κ/λ light chain ratio by flow cytometry in germinal center B cells in Hashimoto thyroiditis. Am J Clin Pathol 2006; 125: 42-48.
99. Matsubayashi S, Tamai H, Morita T, et al. Hashimoto's thyroiditis manifesting monoclonal lymphocytic infiltration. Clin Exp Immunol 1990; 79: 170-174.
100. Saxena A, Alport EC, Moshynska O, Kanthan R, Boctor MA,. Clonal B cell populations in a minority of patients with Hashimoto's thyroiditis. J Clin Pathol 2004; 57: 1258-1263.
101. Hsi ED, Singleton TP, Svoboda SM, Schnitzer B, Ross CW,. Characterization of the lymphoid infiltrate in Hashimoto thyroiditis by immunohistochemistry and polymerase chain reaction for immunoglobulin heavy chain gene rearrangement. Am J Clin Pathol 1998; 110: 327-333.
102. Moshynska OV, Saxena A,. Clonal relationship between Hashimoto thyroiditis and thyroid lymphoma. J Clin Pathol 2008; 61: 438-444.
103. Goatly A, Bacon CM, Nakamura S, et al. FOXP1 abnormalities in lymphoma: Translocation breakpoint mapping reveals insights into deregulated transcriptional control. Mod Pathol 2008; 21: 902-911.
104. Gholam D, Bibeau F, El Weshi A, Bosq J, Ribrag V,. Primary breast lymphoma. Leuk Lymphoma 2003; 44: 1173-1178.
105. Jeon HJ, Akagi T, Hoshida Y, et al. Primary non-Hodgkin malignant lymphoma of the breast. An immunohistochemical study of seven patients and literature review of 152 patients with breast lymphoma in Japan. Cancer 1992; 70: 2451-2459.
106. Cohen PL, Brooks JJ,. Lymphomas of the breast. A clinicopathologic and immunohistochemical study of primary and secondary cases. Cancer 1991; 67: 1359-1369.
107. Thompson PA, Lade S, Webster H, Ryan G, Prince HM,. Effusion-associated anaplastic large cell lymphoma of the breast: Time for it to be defined as a distinct clinico-pathological entity. Haematologica 2010; 95: 1977-1979.
108. Roden AC, Macon WR, Keeney GL, Myers JL, Feldman AL, Dogan A,. Seroma-associated primary anaplastic large-cell lymphoma adjacent to breast implants: An indolent T-cell lymphoproliferative disorder. Mod Pathol 2008; 21: 455-463.
109. de Jong D, Vasmel WL, de Boer JP, et al. Anaplastic large-cell lymphoma in women with breast implants. JAMA 2008; 300: 2030-2035.
110. Al-Khafaji BM, Nestok BR, Katz RL,. Fine-needle aspiration of 154 parotid masses with histologic correlation: Ten-year experience at the University of Texas M. D. Anderson Cancer Center. Cancer 1998; 84: 153-159.
111. Troch M, Formanek M, Streubel B, Mullauer L, Chott A, Raderer M,. Clinicopathological aspects of mucosa-associated lymphoid tissue (MALT) lymphoma of the parotid gland: A retrospective single-center analysis of 28 cases. Head Neck 2011; 33: 763-767.
112. Zenone T,. Parotid gland non-Hodgkin lymphoma in primary Sjogren syndrome. Rheumatol Int, in press.
113. Kassan SS, Thomas TL, Moutsopoulos HM, et al. Increased risk of lymphoma in sicca syndrome. Ann Intern Med 1978; 89: 888-892.
114. Inagaki H,. Mucosa-associated lymphoid tissue lymphoma: Molecular pathogenesis and clinicopathological significance. Pathol Int 2007; 57: 474-484.
115. Baimpa E, Dahabreh IJ, Voulgarelis M, Moutsopoulos HM,. Hematologic manifestations and predictors of lymphoma development in primary Sjogren syndrome: Clinical and pathophysiologic aspects. Medicine (Baltimore) 2009; 88: 284-293.
116. Amador-Ortiz C, Chen L, Hassan A, et al. Combined core needle biopsy and fine-needle aspiration with ancillary studies correlate highly with traditional techniques in the diagnosis of nodal-based lymphoma. Am J Clin Pathol 2011; 135: 516-524.
117. Katz RL,. Modern approach to lymphoma diagnosis by fine-needle aspiration: Restoring respect to a valuable procedure. Cancer 2005; 105: 429-431.
118. Caraway NP,. Strategies to diagnose lymphoproliferative disorders by fine-needle aspiration by using ancillary studies. Cancer 2005; 105: 432-442.